Gilead Sciences, Inc.
Thienopyrimidine derivatives as ACC inhibitors and uses thereof
Last updated:
Abstract:
The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Status:
Grant
Type:
Utility
Filling date:
6 Aug 2020
Issue date:
7 Jun 2022